Skip to main content

Table 3 The Vitiligo European Task Force scores at baseline and week 12, n = 11

From: Ginkgo biloba for the treatment of vitilgo vulgaris: an open label pilot clinical trial

area   % area (SD) staging (0-3) (SD) spreading (-1 to 1) (SD)
head and neck (0-9%) baseline 0.79 (0.94) 1.55 (0.93) 0.73 (0.47)
  week 12 0.73 (0.83) 1.27 (0.90) -0.36 (0.50)
  change -0.06 p = 0.27 -0.27 p = 0.21 -1.09 p = 0.00
trunk (0-36%) baseline 1.33 (1.31) 1.55 (1.04) 0.82 (0.40)
  week 12 1.30 (1.30) 1.45 (1.04) -0.45 (0.52)
  change -0.03 p = 0.21 -0.09 p = 0.36 -1.27 p = 0.00
arms (0-18%) baseline 1.81 (2.17) 1.36 (0.81) 0.55 (0.52)
  week 12 1.77 (2.06) 1.27 (0.79) -0.09 (0.54)
  change -0.05 p = 0.36 -0.09 p = 0.36 -0.64 p = 0.00
legs (0-36%) baseline 1.99 (2.25) 2.09 (0.54) 0.64 (0.50)
  week 12 1.76 (1.76) 1.82 (0.75) -0.27 (0.79)
  change -0.23 p = 0.26 -0.27 p = 0.09 -0.91 p = 0.02
totals (0-100%) baseline 5.91 (4.53) 6.55 (1.92) 2.73 (1.35)
  week 12 5.56 (4.27) 5.82 (1.94) -1.18 (1.25)
  change -0.36 p = 0.10 -0.73 p = 0.10 -3.91 p = 0.00
  1. SD, standard deviation